الرؤساء المشاركون لشركة Cinven الخاصة بالأسهم الخاصة، خورخي كيمادا وبرونو شيك، قدموا جبهة موحدة في أول مقابلة مشتركة لهما منذ أن أدى فضيحة تنظيمية إلى استقالة الرئيس التنفيذي السابق سوبريج راجاجوبالان. wearing matching blue shirts, they emphasized stability and compliance following a £52mn fine upheld by a court for Cinven’s role in illegally increasing NHS drug prices. The firm, managing €45bn in assets, faced criticism over its handling of Italian insurer Eurovita and a shift to three co-managing partners in 2024. Quemada and Schick said they restored investor confidence through transparency and clear leadership during the Competition and Markets Authority investigation.

Cinven is closing a €1.5bn midsized buyout fund and plans a flagship fundraise next year. Recent exits include a €29bn sale of TK Elevator with Advent and a €10bn exit of Stada with Bain Capital, returning 30% of holdings’ value to investors — double the industry average. To prevent recurrence, Cinven has trained teams, upgraded due diligence, and built a 17-person internal legal and compliance team, absent during its 2012 drugmaker investment.